I think Ms. Sampson made an important point, which is that the technology isn't necessarily there on cannabis yet to differentiate between whether it's THC in the blood or cannabinoids. That's a key differentiation in that THC obviously causes impairment and cannabinoids do not. I would note to the panel that it's similar to the fact that breathalyser technology wasn't necessarily there when alcohol was legalized. It's something to take into consideration that this industry will continue to develop. The technology will continue to develop. It's one of those issues that we need to focus on in terms of public safety and public health.
On September 12th, 2017. See this statement in context.